Abstract
Hepatitis C virus (HCV) in kidney transplanted patients (KTx-p) carries a high risk for a worse outcome. This retrospective study evaluates the impact of HCV and of the new direct acting antivirals (DAAs) on patient and graft outcomes in KTx patients. Forty (6.5%) of the 616 KTx-p, who received a kidney transplantation (KTx) in our Centre had antibodies against HCV: 13 were positive for HCV RNA and received DAAs (Group A); 11 were HCV RNA positive and did not receive any treatment (Group B; n = 11); 16 were negative for HCV RNA (Group C). All Group A patients had HCV RNA negativity after 12 weeks of treatment, and 12 (92.30%) achieved a sustained virological response (SVR). Only two patients, who had proteinuria greater than 500 mg/day showed a worsening of proteinuria after antiviral therapy in Group A. Liver enzyme elevation and death were significantly more frequent in Group B than other groups. Our results support the notion that active HCV infection negatively affects kidney recipients and that DAA have a high safety and efficacy profile after KTx with no significant negative effect on allograft function, particularly in well-functioning renal grafts.
| Original language | English |
|---|---|
| Pages (from-to) | 493-501 |
| Number of pages | 9 |
| Journal | Transplant International |
| Volume | 32 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 1 2019 |
Fingerprint
Keywords
- direct acting antivirals
- graft outcome
- hepatitis-C
- kidney transplantation
ASJC Scopus subject areas
- Transplantation
Cite this
Impact of hepatitis C virus and direct acting antivirals on kidney recipients : a retrospective study. / Gendia, Mohamed; Lampertico, Pietro; Alfieri, Carlo Maria; D'Ambrosio, Roberta; Gandolfo, Maria Teresa; Campise, Maria Rosaria; Fabrizi, Fabrizio; Messa, Piergiorgio.
In: Transplant International, Vol. 32, No. 5, 01.05.2019, p. 493-501.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of hepatitis C virus and direct acting antivirals on kidney recipients
T2 - a retrospective study
AU - Gendia, Mohamed
AU - Lampertico, Pietro
AU - Alfieri, Carlo Maria
AU - D'Ambrosio, Roberta
AU - Gandolfo, Maria Teresa
AU - Campise, Maria Rosaria
AU - Fabrizi, Fabrizio
AU - Messa, Piergiorgio
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Hepatitis C virus (HCV) in kidney transplanted patients (KTx-p) carries a high risk for a worse outcome. This retrospective study evaluates the impact of HCV and of the new direct acting antivirals (DAAs) on patient and graft outcomes in KTx patients. Forty (6.5%) of the 616 KTx-p, who received a kidney transplantation (KTx) in our Centre had antibodies against HCV: 13 were positive for HCV RNA and received DAAs (Group A); 11 were HCV RNA positive and did not receive any treatment (Group B; n = 11); 16 were negative for HCV RNA (Group C). All Group A patients had HCV RNA negativity after 12 weeks of treatment, and 12 (92.30%) achieved a sustained virological response (SVR). Only two patients, who had proteinuria greater than 500 mg/day showed a worsening of proteinuria after antiviral therapy in Group A. Liver enzyme elevation and death were significantly more frequent in Group B than other groups. Our results support the notion that active HCV infection negatively affects kidney recipients and that DAA have a high safety and efficacy profile after KTx with no significant negative effect on allograft function, particularly in well-functioning renal grafts.
AB - Hepatitis C virus (HCV) in kidney transplanted patients (KTx-p) carries a high risk for a worse outcome. This retrospective study evaluates the impact of HCV and of the new direct acting antivirals (DAAs) on patient and graft outcomes in KTx patients. Forty (6.5%) of the 616 KTx-p, who received a kidney transplantation (KTx) in our Centre had antibodies against HCV: 13 were positive for HCV RNA and received DAAs (Group A); 11 were HCV RNA positive and did not receive any treatment (Group B; n = 11); 16 were negative for HCV RNA (Group C). All Group A patients had HCV RNA negativity after 12 weeks of treatment, and 12 (92.30%) achieved a sustained virological response (SVR). Only two patients, who had proteinuria greater than 500 mg/day showed a worsening of proteinuria after antiviral therapy in Group A. Liver enzyme elevation and death were significantly more frequent in Group B than other groups. Our results support the notion that active HCV infection negatively affects kidney recipients and that DAA have a high safety and efficacy profile after KTx with no significant negative effect on allograft function, particularly in well-functioning renal grafts.
KW - direct acting antivirals
KW - graft outcome
KW - hepatitis-C
KW - kidney transplantation
UR - http://www.scopus.com/inward/record.url?scp=85064839908&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064839908&partnerID=8YFLogxK
U2 - 10.1111/tri.13393
DO - 10.1111/tri.13393
M3 - Article
VL - 32
SP - 493
EP - 501
JO - Transplant International
JF - Transplant International
SN - 0934-0874
IS - 5
ER -